Mira Keddis is a Nephrology physician affiliated with Mayo Clinic in Arizona. OpenAlex indexes 108 publications with 1,473 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
94.9%Erythropoiesis-stimulating Agent94.9%Darbepoetin alfa100%Part B, office-administered≥14 patientsCardiovascular
2.7%Loop diuretic1%Torsemide100%Part D<11 patientsThiazide-like diuretic1%Indapamide100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
2.4%Metabolic Alkalinizer1.6%Potassium Citrate Er100%Part D<11 patientsPotassium supplement0.8%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
Nephrology Dialysis Transplantation
2024 - Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Journal of Translational Medicine
2023 - GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients
Nephrology Dialysis Transplantation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Caselli, MD
Mayo Clinic in Arizona
Mark Pittelkow, MD
Mayo Clinic in Arizona
John Dibaise, MD
Mayo Clinic in Arizona
Norio Fukami, MD
Mayo Clinic in Arizona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”